CEO of Waterdrop Peng Shen was appointed as Vice-chairman of the Overseas Students and Chinese Committee of the Beijing Youth Federation
BEIJING, Aug. 24, 2022 /PRNewswire/ -- Mr. Peng Shen, Founder, Chairman, and CEO of Waterdrop, took office as the vice chairman of the Overseas Students and Chinese Committee of the Beijing Youth Federation (BYF). BYF is an organization that unites and gathers outstanding youth talents from all walks of life in Beijing, and is a major group that acts on...
MGI Wins IBO Design Gold Award for DNBelab C4 Pocket Single-Cell Lab
SHENZHEN, China, Aug. 24, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, has been awarded Gold by Instrument Business Outlook (IBO) at the 2022 IBO Design Awards for the outstanding design and functionality of its DNBelab C4 Pocket Single-Cell Lab. "MGI is proud to be recognized by IBO for the innovative thinking,...
Everest Medicines Announces Interim Results for First Half of 2022
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, today announced its interim results for first half of 2022 along with a corporate progress update. Everest has made significant progress on all fronts of...
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results. Business Highlights CT053: completed enrollment for pivotal Phase II trial in China, with plan to submit...
MGI Supports the Ministry of Health of Indonesia in the Country’s Breakthrough National Genome Project
JAKARTA, Indonesia, Aug. 24, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, today announced that the National Genome Project in Indonesia has selected MGI technology* as one of the technology providers for the first phase of its effort towards establishing an accountable, accurate, and credible population database of 10,000 whole genomes....
Mangosteen Peel as Medicine – CU’s Faculty of Veterinary Science is Successful in Replicating Mangosteen Peel Extract, Treatment for Intestinal Inflammation in Humans and Animals
BANGKOK, Thailand, Aug. 24, 2022 /PRNewswire/ -- The Faculty of Veterinary Science, Chulalongkorn University has researched and replicated "Hydroxy-xanthones", the vital extracts rich in antioxidants found in mangosteen peels that kill germs and halt infections in the intestinal mucosa. It hopes to expand to include health products for humans and animals in the future. Not only...
Cancer treatment with the world’s smallest rotating gantry began at Yamagata University in 2022: Taking on the challenge of global standardization of heavy ion therapy equipment
SINGAPORE, Aug. 24, 2022 /PRNewswire/ -- In the face of fierce competition among major heavy electric machinery manufacturers, Toshiba delivered Japan's first rotating gantry for heavy ion cancer therapy using superconducting technology to the National Institutes for Quantum Science and Technology (QST) Hospital in 2016. The gantry is the cylindrical, doughnut-like area...
First US Patient Enrolled in SELUTION SLR IDE Peripheral Study
GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ -- The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the US in May 2022, with enrollment of the first patient occurring in Germany one week...
Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies
ROCKVILLE, Md. and SUZHOU, China, Aug. 23, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that the first patient dosing in Australia for its proprietary PD-1/IL-2 bispecific antibody fusion protein (R&D code: IBI363) in...
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
Additions to executive team strengthen global leadership and position Company for strategic long-term growth First-ever product launch of long-acting amubarvimab/romlusevimab combination therapy for COVID-19 in China advances Brii Bio from clinical development to commercial stage biotechnology company On track to advance clinical programs in HBV, CNS, HIV and MDR/XDR, and...
